Cutler Group LP Aldeyra Therapeutics, Inc. Call Options Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 04, 2022	SELL	$2.43 - $4.85 $4,374 - $8,730	-1,800 Reduced 23.08%	6,000 $0
Q1 2022 Apr 14, 2022	SELL	$3.25 - $5.17 $85,475 - $135,971	-26,300 Reduced 77.13%	7,800 $3,000
Q4 2021 Jan 18, 2022	BUY	$3.5 - $9.63 $87,500 - $240,750	25,000 Added 274.73%	34,100 $0
Q3 2021 Oct 26, 2021	BUY	$7.94 - $11.31 $30,172 - $42,978	3,800 Added 71.7%	9,100 $2,000
Q2 2021 Jul 19, 2021	BUY	$10.44 - $14.85 $55,332 - $78,705	5,300 New	5,300 $2,000
Q2 2019 Aug 09, 2019	SELL	$6.0 - $9.0 $33,000 - $49,500	-5,500 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$7.14 - $9.85 $714 - $985	100 Added 1.85%	5,500 $2,000
Q3 2018 Nov 07, 2018	BUY	$6.8 - $14.35 $36,040 - $76,055	5,300 Added 5300.0%	5,400 $16,000
Q2 2018 Aug 10, 2018	BUY	$6.95 - $9.18 $695 - $918	100 New	100 $0

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $283M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.